ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 135 filers reported holding ASCENDIS PHARMA A/S in Q2 2019. The put-call ratio across all filers is 0.27 and the average weighting 1.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2022 | $6,107 | -99.9% | 50,000 | 0.0% | 0.41% | +13.3% |
Q3 2022 | $5,163,000 | +11.1% | 50,000 | 0.0% | 0.36% | +2.8% |
Q2 2022 | $4,648,000 | -20.8% | 50,000 | 0.0% | 0.35% | -22.2% |
Q1 2022 | $5,868,000 | -12.8% | 50,000 | 0.0% | 0.45% | +12.8% |
Q4 2021 | $6,726,000 | -75.2% | 50,000 | -70.6% | 0.40% | -63.7% |
Q3 2021 | $27,096,000 | +174.6% | 170,000 | +126.7% | 1.10% | +228.7% |
Q2 2021 | $9,866,000 | -23.4% | 75,000 | -25.0% | 0.34% | +16.7% |
Q1 2021 | $12,888,000 | -22.7% | 100,000 | 0.0% | 0.29% | -27.7% |
Q4 2020 | $16,678,000 | -13.5% | 100,000 | -20.0% | 0.40% | -46.5% |
Q3 2020 | $19,290,000 | -25.5% | 125,000 | -28.6% | 0.74% | -24.9% |
Q2 2020 | $25,883,000 | -61.7% | 175,000 | -70.8% | 0.99% | -68.5% |
Q1 2020 | $67,567,000 | -25.3% | 600,000 | -7.7% | 3.14% | -13.0% |
Q4 2019 | $90,428,000 | +30.7% | 650,000 | -9.5% | 3.61% | -14.3% |
Q3 2019 | $69,187,000 | -7.6% | 718,300 | +10.5% | 4.21% | -2.0% |
Q2 2019 | $74,848,000 | +6.0% | 650,000 | +8.3% | 4.30% | -9.9% |
Q1 2019 | $70,620,000 | +233.1% | 600,000 | +77.3% | 4.77% | +177.2% |
Q4 2018 | $21,204,000 | -14.5% | 338,456 | -3.3% | 1.72% | +6.8% |
Q3 2018 | $24,801,000 | +0.3% | 350,000 | -5.8% | 1.61% | -11.9% |
Q2 2018 | $24,728,000 | +1.7% | 371,739 | 0.0% | 1.83% | +1.0% |
Q1 2018 | $24,312,000 | +102.3% | 371,739 | +23.9% | 1.81% | +44.0% |
Q4 2017 | $12,018,000 | +329.2% | 300,000 | +200.0% | 1.26% | +209.1% |
Q1 2017 | $2,800,000 | -14.7% | 100,000 | -38.4% | 0.41% | -8.1% |
Q4 2016 | $3,284,000 | +162.5% | 162,254 | +160.6% | 0.44% | +221.0% |
Q3 2016 | $1,251,000 | +51.5% | 62,254 | 0.0% | 0.14% | +17.9% |
Q2 2016 | $826,000 | -27.6% | 62,254 | +1.2% | 0.12% | -32.0% |
Q1 2016 | $1,141,000 | +1.2% | 61,500 | 0.0% | 0.17% | +27.4% |
Q4 2015 | $1,127,000 | +3.5% | 61,500 | 0.0% | 0.14% | -22.4% |
Q3 2015 | $1,089,000 | +0.2% | 61,500 | 0.0% | 0.17% | +20.0% |
Q2 2015 | $1,087,000 | +1.9% | 61,500 | 0.0% | 0.14% | -12.1% |
Q1 2015 | $1,067,000 | – | 61,500 | – | 0.16% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Vivo Capital, LLC | 2,003,147 | $225,574,000 | 20.44% |
RA Capital Management | 4,914,955 | $553,473,000 | 17.48% |
Sofinnova Investments, Inc. | 1,109,874 | $124,983,000 | 11.56% |
Eversept Partners, LP | 275,494 | $31,023,379 | 7.71% |
Avoro Capital Advisors LLC | 1,787,000 | $201,234,000 | 6.79% |
Orbimed Advisors | 3,287,400 | $370,194,000 | 6.22% |
Eventide Asset Management | 1,698,648 | $191,285,000 | 6.19% |
Logos Global Management LP | 120,000 | $13,513,000 | 5.14% |
Ghost Tree Capital, LLC | 150,000 | $16,892,000 | 4.48% |
Spyglass Capital Management LLC | 351,388 | $39,570,000 | 4.47% |